



# A Primer on Prevention, Recognition and Management of Aortic PVL

Monday, October 27th 2025; 4:50 PM - 4:58 PM

Hasan Jilaihawi, MD



Interventional Cardiologist

Director, Multimodality Imaging Corelab

Professor of Cardiology, Smidt Heart Institute

Cedars-Sinai Medical Center,

Los Angeles, CA



TRANSCATHETER  
CARDIOVASCULAR  
THERAPEUTICS®

# ***Disclosure of Relevant Financial Relationships***

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

## **Nature of Financial Relationship**

Grant/Research Support

Consultant Fees/Honoraria

Individual Stock(s)/Stock Options

Scientific Advisory Board

## **Ineligible Company**


Pi-Cardia

Edwards Lifesciences, Medtronic


DASI simulations

DASI simulations, Pi-Cardia

# A Primer on Prevention, Recognition and Management of Aortic PVL



# Prevention of Aortic PVL




# First, a History lesson!

## It is the year 2010.....



*Instagram is launched  
Facebook surpasses 500m Users*



*Apple releases the  
first iPad*



*Justin Bieber explodes to fame  
with "Bieber Fever"*



.....and aortic paravalvular leak (PVL) is a **major** and relatively **common** predictor of mortality after TAVR

Study	No. of patients	Significant PV AR, n (%)	Follow-up	HR (95% CI) (multivariable)
Sinning et al	146	22 (15.0)	Up to 1 year	<b>2.4 (1.0–5.4)</b>
Tamburino et al	663	139 (21.0)	Median 18 months	<b>3.79 (1.57-9.10)</b>
Moat et al	877	115/849 (13.6)	> 11 months	<b>1.66 (1.10–2.51)</b>
Gilard et al	3195	316/1915 (16.5)	Median 114 days	<b>2.49 (1.91-3.25)</b>
Abdel-Wahab	690	119 (17.2)	In-hospital	<b>2.43 (1.22-4.85)</b>
Vasa-Nicotera et al	122	20 (16.3)	1-year	<b>4.19 (2.05-8.59)</b>


**AND 3D measurements are not used for TAVR in the PARTNER trial!**

26 mm Edwards SAPIEN

Severe, dynamic **fatal PVL** with a rocking valve




# Cross-sectional CT is a better measure of annular size than 2D TEE



Smallest 2D TEE  
measurement used for  
annular sizing: **21.6 mm**  
Retrospective measurement  
of annular area: **797mm<sup>2</sup>**

**Gross undersizing**  
resulted in severe AR  
and a rocking valve


# Cedars-Sinai data: Cross-sectional CT vs 2D TEE



*Cross-sectional CT  
measures have  
greater  
discriminatory  
value for PVL than  
largest 2D TEE  
measurement*


# Evidence for 3D TEE?

## 3D TEE (Qlab) vs 2D TEE





*Cross-sectional 3D  
TEE measures have  
greater discriminatory  
value for PVL than  
largest 2D TEE  
meaurement*

# Not only 3D sizing but also device iterations mitigate PVL Heavily calcified AS with LVOT calcium





## 29 S3 in heavily calcified AS with LVOT calcium



# Sealing skirt mitigates PVL with severe LVOT calcium Now improved further with S3UR



Nodule of calcium prevents full expansion  
BUT Zero PVL=no malapposition








*Several other platforms also incorporate the benefit of the sealing skirt*



# Bicuspid Mega-annulus

75 yo male

Non-ischemic cardiomyopathy; ICD; LFLG AS  
EF 27%; DI 0.2; AVA 0.5; Mean PG 14 mmHg



Type 1 LR  
Non-calcified  
raphe;  
**AoMAX 44 mm**



# What are the concerns?


- Embolization / Migration
- Paravalvular leak

# DASI Simulation: ROM (Reduced Order Modeling)


Min(mm)/Max(mm)	BE 29 Nominal	+3cc	+5cc
Inflow	26.8/27.4	27.7/28.1	28.8/28.9
Waist	24.8/25.2	27.0/27.1	28.5/28.9
Outflow	27.4/27.8	28.3/28.5	29.2/29.4




BE 29 Nominal



BE 29 +3cc




BE 29 +5cc



**Waist at nominal deployment implies device stability**

# Simulation: 29 S3 Root Rupture Risk


Left-Right Cusp  
Non-Coronary Cusp



These simulations are under evaluation by the Food and Drug Administration. This product is not approved to diagnose, treat, cure, or prevent any disease. DASI Simulations provides simulations for several THV deployment options. Simulations can cover a mix of appropriate and suboptimal options. Appropriate alternatives may exist. Content is not intended to establish or recommend a standard of care to be followed. Physicians and other health care practitioners should exercise independent professional judgment and use the simulation results in conjunction with the THV's Instruction-for-Use, the patient's clinical history, symptoms, and other preprocedural evaluations for TAVR


# Balloon-Expandable 29 Nominal PVL Risk

Left-Right Cusp  
Non-Coronary Cusp




BE 29 Nominal

	BE 29 Nominal
Gap distance	1.0mm; 1.9mm



BE 29 +3cc

	BE 29 +3cc
Gap distance	0.9mm; 1.7mm



BE 29 +5cc

	BE 29 +5cc
Gap distance	0.7mm; 1.4mm


**Gaps  $\geq 2$  mm  
may =  $\uparrow$  PVL  
(S3U)**

**Gaps  $< 2$  mm  
Implies no significant  
PVL**


\*Threshold is yet to be determined. Please use clinical judgement.

These simulations are under evaluation by the Food and Drug Administration. This product is not approved to diagnose, treat, cure, or prevent any disease. DASI Simulations provides simulations for several THV deployment options. Simulations can cover a mix of appropriate and suboptimal options. Appropriate alternatives may exist. Content is not intended to establish or recommend a standard of care to be followed. Physicians and other health care practitioners should exercise independent professional judgment and use the simulation results in conjunction with the THV's Instruction-for-Use, the patient's clinical history, symptoms, and other preprocedural evaluations for TAVR

# Bicuspid Mega-annulus




**29 S3U  
Deployed @  
Nominal with  
post-dil x1**



**No PVL  
Mean AV  
gradient 4  
mmHg  
EF ↑ to 34%**


# Recognition of Aortic PVL




# Know which anatomies to have a high expectation for PVL!

Risk phenotype-

73-year-old male with Type 1 L-R fusion and calcified raphe






**CT risk phenotype: High**  
**Plan: 29 mm S3 – Double tap**



- PROCEDURE
- Cerebral protection using Sentinel device
- Transcatheter Aortic Valve Implantation using 29 mm Sapien 3 Ultra Resilia

#MAXIMALIST!




Pre-dilatation with 22mm Z MED II


Initial deployment with -4 cc

Post dilatation with -2 cc

# Final result




Intra-procedure TEE






Discharge TTE


**Circular deployment – good hemodynamics  
Elucidated definitively on TEE**



# Transcatheter hemodynamics can help evaluate *prognostically significant* aortic PVL




# Transcatheter hemodynamics can help evaluate *prognostically significant* aortic PVL




Jilaihawi et al, EuroIntervention 2015;11:456-464

# Management of Aortic PVL





# Management of Aortic PVL – decision making





# 88-year-old male with Type 1 L-R fusion



**CT risk phenotype: High**



SOV	Area:	1568	Peri:	142
LVOT	Area:	694.3	Peri:	95.4
Coronary Height	RCA:	14.8	LCA:	16.4




- PROCEDURE
- Cerebral protection using Sentinel device
- Transcatheter Aortic Valve Implantation using 29 mm Sapien 3







Pre-dilatation with 20mm Z MED II

Initial deployment with  
nominal volume





Post-dilatation with  
nominal volume



# Persistent PVL due to calcium



**12mm  
AVP II  
Plug**



*Patient presents to CSMC with BVD (PVL+AS) in 2024  
(26 S3 outside institution in 2022)*



*Significant paravalvular leak*


*Restricted bioprosthetic leaflet motion*

*Transesophageal Echocardiogram*


**Outflow: 26.5 mm**




**Mild: 25.6 mm**




**Inflow: 26.5 mm**



**CT shows *in vitro* sizing for 26 S3 but with *large LVOT***




**Ao Max: 42.7 mm**



**Larger LVOT**

**LVOT: A619**



**Commissurally aligned; Calcified Leaflets; Minimal waist**


# Pre-index TAVR CT, prior to index TAVR in 2022

## Type 1 LR bicuspid non-calcified raphe


**Annulus: 576 mm<sup>2</sup>**



**SOV: 38.8 x 39.9 x 38.4 mm**



**STJ 38.6 x 39.1 mm**





Area derived Ø: 26.9 mm  
Perimeter derived Ø: 27.2 mm  
Area: 566.7 mm<sup>2</sup>  
Perimeter: 85.4 mm  
Min. Ø: 24.1 mm  
Max. Ø: 29.7 mm  
Avg. Ø: 26.9 mm  
Distance: 4.0 mm


Phase: 20.0%




**LVOT: 566 mm<sup>2</sup>**




# *Redo TAV: 29 S3UR*



***Cerebral Embolic  
Protection using  
Sentinel***




***Deployment of 29mm  
Sapien 3 Ultra Resilia at  
nominal volume***






***Post-dilatation with the  
Commander balloon at  
nominal volume***

# Final Result



# Discharge



# A Primer on Prevention, Recognition and Management of Aortic PVL

- All 3 are heavily dependent on imaging:
- Prevention:
  - Size optimally using 3D imaging, consider simulation
  - Optimize procedurally- predil/postdil
- Recognition:
  - Underestimated by TTE, take clinical cues to have low threshold for TEE
  - Hemodynamics can prognosticate
- Management:
  - Understand the mechanism to best guide safe and effective management